Max Klement

Max Klement is a seasoned professional in venture investments, currently serving as Principal at Novo Holdings since May 2022. Prior experience includes roles as Principal at BGV (BioGeneration Ventures) from January 2019 to May 2022, where involvement included serving as Board Director at Complement Therapeutics and Board Observer at multiple biotech firms. Klement has held various senior positions in project management and process development at Eden Biologics and Hummingbird Bioscience. Early career experience includes research fellowship at A*STAR and contributions to the United Nations ESCAP. Educational qualifications include an MBA from INSEAD, a Ph.D. in Chemical and Biomolecular Engineering from the National University of Singapore, and a B.S. in Chemical Engineering from UC Irvine.